AVB-620 is an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer.

AVB-620 is currently being evaluated in a phase 1b clinical study in breast cancer patients. The initial indication is intraoperative identification of primary tumor extent and metastatic lymph nodes in breast cancer patients. AVB-620 hopes to address a large unmet medical need as 20%-40% of breast cancer patients are subjected to additional surgeries due to incomplete removal of the primary tumor or lymph node metastases. AVB-620 displayed outstanding preclinical data with sensitivity of >95% in preclinical breast cancer models and 100% in ex vivo analysis of human breast cancer tissue.

Learn more »